André Lescarbeau

Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)

Martin Tremblay, André Lescarbeau, Michael J. Grogan et al. · Journal of Medicinal Chemistry · 2009 · 250 citations · Full text

Medicinal Chemistry, Compound 28, Pharmaceutical Science +13

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate

Catherine A. Evans, Tao Liu, André Lescarbeau et al. · ACS Medicinal Chemistry Letters · 2016 · 146 citations · Full text

Immunology, Robust Inhibition, -γ Inhibitor +17

Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors

Tao Liu, Somarajan Nair, André Lescarbeau et al. · Journal of Medicinal Chemistry · 2012 · 80 citations · Full text

Drug Target, Simplified Analogues, Compounds 74 +17

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

Andreas Varkaris, Ermira Pazolli, Hakan Günaydin et al. · Cancer Discovery · 2023 · 80 citations · Full text

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2

Heike Schönherr, Pelin Ayaz, Alexander M. Taylor et al. · Proceedings of the National Academy of Sciences · 2024 · 53 citations · Full text